The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer
Open accessAbstract
BACKGROUND: ) mutation-positive advanced non-small-cell lung cancer (NSCLC). The efficacy and safety of osimertinib as adjuvant therapy are unknown. METHODS: mutation-positive NSCLC in a 1:1 ratio to receive either osimertinib (80 mg once daily) or placebo for 3 years. The primary end point was disease-free survival among patients with stage II to IIIA disease (according to investigator assessment). The secondary end points included disease-free survival in the overall population of patients with stage IB to IIIA disease, overall survival, and safety. RESULTS: A total of 682 patients underwent randomization (339 to the osimertinib group and 343 to the placebo group). At 24 months, 90% of the patients with stage II to IIIA disease in the osimertinib group (95% confidence interval [CI], 84 to 93) and 44% of those in the placebo group (95% CI, 37 to 51) were alive and disease-free (overall hazard ratio for disease recurrence or death, 0.17; 99.06% CI, 0.11 to 0.26; P<0.001). In the overall population, 89% of the patients in the osimertinib group (95% CI, 85 to 92) and 52% of those in the placebo group (95% CI, 46 to 58) were alive and disease-free at 24 months (overall hazard ratio for disease recurrence or death, 0.20; 99.12% CI, 0.14 to 0.30; P<0.001). At 24 months, 98% of the patients in the osimertinib group (95% CI, 95 to 99) and 85% of those in the placebo group (95% CI, 80 to 89) were alive and did not have central nervous system disease (overall hazard ratio for disease recurrence or death, 0.18; 95% CI, 0.10 to 0.33). Overall survival data were immature; 29 patients died (9 in the osimertinib group and 20 in the placebo group). No new safety concerns were noted. CONCLUSIONS: mutation-positive NSCLC, disease-free survival was significantly longer among those who received osimertinib than among those who received placebo. (Funded by AstraZeneca; ADAURA ClinicalTrials.gov number, NCT02511106.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citationOsimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Self-citationRosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
CLOPPER, C. J., & PEARSON, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,003
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379
Self-citationSequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
Self-citationEpidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
Ramalingam, S. S., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., Zhou, C., Reungwetwattana, T., Cheng, Y., Chewaskulyong, B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913662 · Cited by 2,914
Self-citationLung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Pignon, J.-P., Tribodet, H., Scagliotti, G. V., Douillard, J.-Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9030 · Cited by 2,642
Self-citation
Cited by
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Forde, P. M., Spicer, J., Lu, S., Provencio, M., Mitsudomi, T., Awad, M. M., Felip, E., Broderick, S. R., Brahmer, J. R., Swanson, S. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2202170 · Cited by 2,825
The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015
Nicholson, A. G., Tsao, M. S., Beasley, M. B., Borczuk, A. C., Brambilla, E., Cooper, W. A., Dacic, S., Jain, D., Kerr, K. M., Lantuejoul, S., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.11.003 · Cited by 1,554
Felip, E., Altorki, N., Zhou, C., Csőszi, T., Vynnychenko, I., Goloborodko, O., Luft, A., Akopov, A., Martinez-Marti, A., Kenmotsu, H., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02098-5 · Cited by 1,486
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0025 · Cited by 1,392
Toward personalized treatment approaches for non-small-cell lung cancer
Wang, M., Herbst, R. S., & Boshoff, C. (2021) · Nature Medicine · doi:10.1038/s41591-021-01450-2 · Cited by 1,093
Self-citationKinase drug discovery 20 years after imatinib: progress and future directions
Cohen, P., Cross, D., & Jänne, P. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00195-4 · Cited by 1,024
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0013 · Cited by 948
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
Tan, A. C., & Tan, D. S. W. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01626 · Cited by 779
O’Brien, M., Paz-Ares, L., Marreaud, S., Dafni, U., Oselin, K., Havel, L., Esteban, E., Isla, D., Martinez-Marti, A., Faehling, M., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00518-6 · Cited by 774
Self-citationOsimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC
Planchard, D., Jänne, P. A., Cheng, Y., Yang, J. C.-H., Yanagitani, N., Kim, S.-W., Sugawara, S., Yu, Y., Fan, Y., Geater, S. L., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306434 · Cited by 740
Self-citationRolfo, C., Mack, P., Scagliotti, G. V., Aggarwal, C., Arcila, M. E., Barlesi, F., Bivona, T., Diehn, M., Dive, C., Dziadziuszko, R., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.06.017 · Cited by 683
Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC
Tsuboi, M., Herbst, R. S., John, T., Kato, T., Majem, M., Grohé, C., Wang, J., Goldman, J. W., Lu, S., Su, W.-C., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304594 · Cited by 672
Self-citationNon‐small cell lung cancer in China
Chen, P., Liu, Y., Wen, Y., & Zhou, C. (2022) · Cancer Communications · doi:10.1002/cac2.12359 · Cited by 656
Hendriks, L. E. L., Remon, J., Faivre-Finn, C., Garassino, M. C., Heymach, J. V., Kerr, K. M., Tan, D. S. W., Veronesi, G., & Reck, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00551-9 · Cited by 568
Overcoming therapy resistance in EGFR-mutant lung cancer
Passaro, A., Jänne, P. A., Mok, T., & Peters, S. (2021) · Nature Cancer · doi:10.1038/s43018-021-00195-8 · Cited by 565
Remon, J., Soria, J.-C., & Peters, S. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.1994 · Cited by 470
Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer
Wu, Y.-L., Dziadziuszko, R., Ahn, J. S., Barlesi, F., Nishio, M., Lee, D. H., Lee, J.-S., Zhong, W., Horinouchi, H., Mao, W., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2310532 · Cited by 431
Self-citationHerbst, R. S., Wu, Y.-L., John, T., Grohe, C., Majem, M., Wang, J., Kato, T., Goldman, J. W., Laktionov, K., Kim, S.-W., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02186 · Cited by 408
Self-citationFu, K., Xie, F., Wang, F., & Fu, L. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01391-4 · Cited by 397
Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer
Chaft, J. E., Rimner, A., Weder, W., Azzoli, C. G., Kris, M. G., & Cascone, T. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00501-4 · Cited by 375
Single-cell spatial landscapes of the lung tumour immune microenvironment
Sorin, M., Rezanejad, M., Karimi, E., Fiset, B., Desharnais, L., Perus, L. J. M., Milette, S., Yu, M. W., Maritan, S. M., Doré, S., et al. (2023) · Nature · doi:10.1038/s41586-022-05672-3 · Cited by 367
Advances in systemic therapy for non-small cell lung cancer
Miller, M., & Hanna, N. (2021) · BMJ · doi:10.1136/bmj.n2363 · Cited by 366
Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
Lu, S., Kato, T., Dong, X., Ahn, M.-J., Quang, L.-V., Soparattanapaisarn, N., Inoue, T., Wang, C.-L., Huang, M., Yang, J. C.-H., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2402614 · Cited by 346
Self-citationTargeting KRAS in non-small-cell lung cancer: recent progress and new approaches
Reck, M., Carbone, D. P., Garassino, M., & Barlesi, F. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.06.001 · Cited by 326
Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy
Topalian, S. L., Forde, P. M., Emens, L. A., Yarchoan, M., Smith, K. N., & Pardoll, D. M. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.07.011 · Cited by 317
Lu, S., Dong, X., Jian, H., Chen, J., Chen, G., Sun, Y., Ji, Y., Wang, Z., Shi, J., Lu, J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02641 · Cited by 303
Self-citationThe blood–tumour barrier in cancer biology and therapy
Steeg, P. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00529-6 · Cited by 287
Management of Stage III Non–Small-Cell Lung Cancer: ASCO Guideline
Daly, M. E., Singh, N., Ismaila, N., Antonoff, M. B., Arenberg, D. A., Bradley, J., David, E., Detterbeck, F., Früh, M., Gubens, M. A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02528 · Cited by 283
Le Pechoux, C., Pourel, N., Barlesi, F., Lerouge, D., Antoni, D., Lamezec, B., Nestle, U., Boisselier, P., Dansin, E., Paumier, A., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00606-9 · Cited by 276
Zhong, W.-Z., Wang, Q., Mao, W.-M., Xu, S.-T., Wu, L., Wei, Y.-C., Liu, Y.-Y., Chen, C., Cheng, Y., Yin, R., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01820 · Cited by 273
Self-citationFelip, E., Altorki, N., Zhou, C., Vallières, E., Martínez-Martí, A., Rittmeyer, A., Chella, A., Reck, M., Goloborodko, O., Huang, M., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.07.001 · Cited by 263
Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology
Mithoowani, H., & Febbraro, M. (2022) · Current Oncology · doi:10.3390/curroncol29030150 · Cited by 259
Zhang, J.-T., Liu, S.-Y., Gao, W., Liu, S.-Y. M., Yan, H.-H., Ji, L., Chen, Y., Gong, Y., Lu, H.-L., Lin, J.-T., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1486 · Cited by 228
“Encouragingly, substantial progress has been made since the introduction of tyrosine kinase inhibitors and immune-checkpoint inhibitors (ICI), as reported in the ADAURA and IMpower 010 trials (4, 5).”
BackgroundNagasaka, M., Zhu, V. W., Lim, S. M., Greco, M., Wu, F., & Ou, S.-H. I. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.11.028 · Cited by 219
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Peng, T., Ma, X., Hua, W., Wang, C., Chu, Y., Sun, M., Fermi, V., Hamelmann, S., Lindner, K., Shao, C., et al. (2025) · Cell Stem Cell · doi:10.1016/j.stem.2025.01.002 · Cited by 86
Self-citationAdvances and future directions in ROS1 fusion-positive lung cancer
Boulanger, M. C., Schneider, J. L., & Lin, J. J. (2024) · The Oncologist · doi:10.1093/oncolo/oyae205 · Cited by 38
Han, L., Zhang, X., Wang, Z., Zhang, X., Zhao, L., Fu, W., Liang, X., Zhang, Z., & Wang, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.665253 · Cited by 31
Osimertinib Covalently Binds to CD34 and Eliminates Myeloid Leukemia Stem/Progenitor Cells
Xia, L., Liu, J.-Y., Yang, M.-Y., Zhang, X.-H., Jiang, Y., Yin, Q.-Q., Luo, C.-H., Liu, H.-C., Kang, Z.-J., Zhang, C.-T., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-1632 · Cited by 5
Metadata
- Authors
- Wu, Y.-L., Tsuboi, M., He, J., John, T., Grohe, C., Majem, M., Goldman, J. W., Laktionov, K., Kim, S.-W., Kato, T., Vu, H.-V., Lu, S., Lee, K.-Y., Akewanlop, C., Yu, C.-J., de Marinis, F., Bonanno, L., Domine, M., Shepherd, F. A., Zeng, L., Hodge, R., Atasoy, A., Rukazenkov, Y., & Herbst, R. S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-10-29
- Volume
- 383
- Issue
- 18
- Pages
- 1711-1723
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3087210493
- Cited by
- 1,798
- References
- 47
- FWCI
- 130.28
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.